<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402427</url>
  </required_header>
  <id_info>
    <org_study_id>SHCCARD-001</org_study_id>
    <nct_id>NCT01402427</nct_id>
  </id_info>
  <brief_title>Is Verapamil In TransRadial Interventions OmittabLe?</brief_title>
  <acronym>VITRIOL</acronym>
  <official_title>Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Health Center, Hungary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Health Center, Hungary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Verapamil is traditionally applied prophylactically in transradial procedures to
      prevent radial artery spasm. However, verapamil may have side effects and is contraindicated
      in some clinical settings.

      Methods: During an investigator‐initiated, randomized, double‐blind trial, we evaluate the
      need for preventive verapamil administration. After vascular access is established, patients
      receive either 5 mg verapamil (n=297) or placebo (n=294). We compare the rate of access site
      conversions as primary end point using a superiority margin of 5%. Occurrence of code breaks
      (composite of conversions and unplanned use of verapamil), overall verapamil use, procedural
      and fluoroscopic times, contrast volume, and subjective pain are investigated as secondary
      end points.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Access Site Conversions</measure>
    <time_frame>Occurrence of access site conversion will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Code Breaks</measure>
    <time_frame>Occurrence of code breaking will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
    <description>Code break: a composite of access site conversion and unplanned use of vasodilators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Vasodilator Use</measure>
    <time_frame>Vasodilator use will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Time</measure>
    <time_frame>Procedural time will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic Time</measure>
    <time_frame>Fluoroscopic time will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Volume</measure>
    <time_frame>The amount of contrast medium will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Pain</measure>
    <time_frame>Subjective pain will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
    <description>Analysis of the rates of signiﬁcant pain deﬁned as pain score ≥4 on a semiquantitative scale ranging from 1 to 6.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">591</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Verapamil Toxicity</condition>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intraarterial administration of 10 mL saline.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing transradial coronary angiography and/or percutaneous coronary
             intervention

          -  successful cannulation of the radial artery

        Exclusion Criteria:

          -  reduced left ventricular systolic function (LVEF&lt;35%)

          -  significant aortic stenosis

          -  bradycardia (&lt;50/min.)

          -  myocardial infarction complicated by cardiogenic shock and/or high grade AV block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Istvan Hizoh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Center, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Gabor Kiss, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>State Health Center, Budapest, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Health Center</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <results_reference>
    <citation>Hizoh I, Majoros Z, Major L, Gulyas Z, Szabo G, Kerecsen G, Korda A, Molnar F, Kiss RG. Need for prophylactic application of verapamil in transradial coronary procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial Interventions OmittabLe?) trial. J Am Heart Assoc. 2014 Apr 14;3(2):e000588. doi: 10.1161/JAHA.113.000588.</citation>
    <PMID>24732918</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <results_first_submitted>April 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Health Center, Hungary</investigator_affiliation>
    <investigator_full_name>Istvan Hizoh, MD, PhD</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Angiography</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Transradial</keyword>
  <keyword>Radial Artery Spasm</keyword>
  <keyword>Verapamil</keyword>
  <keyword>Adverse Effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Verapamil</title>
          <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Intraarterial administration of 10 mL saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Verapamil</title>
          <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Intraarterial administration of 10 mL saline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="297"/>
            <count group_id="B2" value="294"/>
            <count group_id="B3" value="591"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="10.5"/>
                    <measurement group_id="B2" value="62.5" spread="10.8"/>
                    <measurement group_id="B3" value="62.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Access Site Conversions</title>
        <time_frame>Occurrence of access site conversion will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Access Site Conversions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.011</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Code Breaks</title>
        <description>Code break: a composite of access site conversion and unplanned use of vasodilators.</description>
        <time_frame>Occurrence of code breaking will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Code Breaks</title>
          <description>Code break: a composite of access site conversion and unplanned use of vasodilators.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Vasodilator Use</title>
        <time_frame>Vasodilator use will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Vasodilator Use</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Time</title>
        <time_frame>Procedural time will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Time</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="10.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="16.0" lower_limit="9.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopic Time</title>
        <time_frame>Fluoroscopic time will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopic Time</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="2.4" upper_limit="10.7"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.1" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Volume</title>
        <time_frame>The amount of contrast medium will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Volume</title>
          <units>milliliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="47.0" upper_limit="156.5"/>
                    <measurement group_id="O2" value="72.5" lower_limit="48.0" upper_limit="146.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Pain</title>
        <description>Analysis of the rates of signiﬁcant pain deﬁned as pain score ≥4 on a semiquantitative scale ranging from 1 to 6.</description>
        <time_frame>Subjective pain will be assessed within 1 minute after completion of coronary angiography or intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verapamil</title>
            <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Intraarterial administration of 10 mL saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Pain</title>
          <description>Analysis of the rates of signiﬁcant pain deﬁned as pain score ≥4 on a semiquantitative scale ranging from 1 to 6.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Verapamil</title>
          <description>Verapamil: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Intraarterial administration of 10 mL saline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was conducted in a single, high-volume institution by experienced operators. The results may not be applicable to lower-volume centers or to operators with less experience.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Istvan Hizoh, MD, PhD / Senior Consultant</name_or_title>
      <organization>State Health Center, Hungary</organization>
      <phone>+36 1 4651800 ext 71773</phone>
      <email>ihizoh@web.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

